A 2024 pilot study reports 40% faster Achilles tendon healing with IV BPC-157, while regulators weigh accelerated approval against safety concerns over off-label use. New clinical data on intravenous ...
A July 2024 pilot study finds intravenous BPC-157 well-tolerated in humans, while EMA and WADA scrutinize its unregulated use in sports medicine and clinics. New human trial data reveals BPC-157’...
Recent breakthroughs in herbal cubosome technology offer promising solutions for arthritis treatment, improving bioavailability and reducing side effects through advanced nanotechnology. Cutting-edge ...
